News for Mind Medicine (MindMed) Inc. (MMEDF)

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NMNMD.OQ - Mind Medicine (MindMed) IncQ4 2024 Mind Medicine (MindMed) Inc Earnings CallMar 06,

The following slide deck was published by Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsStephanie Fagan - Chief Corporate...

–First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data…

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ”œCompany” or ”œMindMed”), a late-stage clinical biopharmaceutical company developing novel product cand

– Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Sca…

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Mind Medicine CEO Robert Barrow sells shares worth $141,957

Mind Medicine's chief legal officer sells $33,576 in stock

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to tr

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to tr

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the ”œCompany” or ”œMindMed”), a clinical-stage biopharmaceutical company developing novel product candidate

NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates…

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to tr

Discover promising investment ideas on lesser covered stocks featuring EPR Properties, Gilead Sciences, BMW and more. Click here to read more.

Loading... Loading... Shares of Stitch Fix, Inc. SFIX rose sharply in today's pre-market trading following better-than-expected third-quarter financial results...

Shares of Robinhood Markets, Inc. (NASDAQ: HOOD) rose sharply in today’s pre-market trading after the company reported February trading metrics.

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.